Connect with us
Prague Gaming & TECH Summit 2025 (25-26 March)

Fintech PR

NeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline

Published

on

neophore-raises-an-additional-96m-(usd-$12.2m)-series-b-financing-extension-to-further-progress-drug-discovery-pipeline
  • Italian investors, NEVA SGR, LIFTT and Simon Fiduciaria, join the existing syndicate
  • Additional investment brings the total Series B financing to £31.1 million (approx. USD $39.5 million)

LONDON, Feb. 1, 2024 /PRNewswire/ — NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces a further extension of £9.6m (approx. USD $12.2m) to its Series B financing round. With participation from its existing syndicate, CPF managed by Sixth Element Capital, Claris Ventures, Astellas Venture Management, 3B Future Health Fund, 2investAG, and the addition of three new investors – NEVA SGR (the venture capital arm of Intesa Sanpaolo banking group), LIFTT (the venture capital focused on deep-tech chaired by Stefano Buono) and Simon Fiduciaria (the fiduciary company of Ersel Group). This extension brings the total raised in Series B financing to £31.1m (approx. USD $39.5m).

NeoPhore is building a pipeline of small molecule drugs targeting novel proteins across the DNA mismatch repair (‘MMR’) pathway to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. NeoPhore’s first-in-class MMR inhibitors induce neoantigen expression and increase immunogenicity in solid tumours that become exquisitely sensitive to immunotherapy.

2023 was a great year of progress for NeoPhore. At AACR-NCI-EORTC in Boston in October, the first disclosure of lead compound NP1867 was presented. This demonstrated that NP1867 functionally inhibits MMR in cells and elicits COSMIC mutational signatures consistent with MMR-deficient patient samples.

The additional Series B funding will be used to progress NeoPhore’s lead oral program, through early pre-clinical development.

Dr Matthew Baker, Chief Executive Officer of NeoPhore, said: “NeoPhore has made excellent progress throughout 2023. With the support of our committed and new investors, along with our research collaborations with academic institutions that are in place, we remain on track to deliver a candidate drug for our lead PMS2 program by early 2025.”

Dr Robert James, Chairman of NeoPhore, said: “Over the past years NeoPhore has made tremendous strides in showing that it is possible to target the MMR pathway with small molecule inhibitors.  The recent data the Company has generated and presented at an international conference leads us to believe that NeoPhore’s approach may be profoundly important.  We are pleased to welcome three new Italian-based investors to our syndicate as well as further funding from existing investors. Their commitment reflects the potential value of NeoPhore’s approach that exploits the dynamics of cancer neoantigen evolution, through the discovery and design of effective, well-tolerated medicines that will become a key part of the next-generation of cancer immunotherapies. We are very excited about the next stage in the life of the Company.”

About NeoPhore Ltd

NeoPhore, UK is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. Generation of cancer neoantigens in tumours can be exploited by the patients’ immune system to overcome natural defence mechanisms in cancer. The Company’s approach targets the DNA mismatch repair (MMR) pathway, which has been proven to promote neoantigen creation and subsequent immunity against numerous cancers. Using these insights, NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. NeoPhore was spun-out of the University of Turin and PhoreMost Ltd by the CRT Pioneer Fund. For more information, please visit www.neophore.com

About NEVA SGR

Neva SGR, venture capital arm of the Intesa Sanpaolo Group and wholly owned by the Intesa Sanpaolo Innovation Center, plans and manages investment funds for professional investors interested in seizing diversification and high-yield opportunities offered by Venture Capital investments. Neva SGR can count on Intesa Sanpaolo Innovation Center’s and Intesa Sanpaolo Group’s strength, financial resources, know-how and network of relationships, a unique source of value on the market. Neva SGR can watch trends and markets from a privileged position and takes action with the strength and the responsibility of Italy’s leading banking group. Intesa Sanpaolo Innovation Center has invested in Neva First, the investment fund designed for excellent, high-tech, high-innovation start-ups, which take advantage of trends with exponential growth potential.

To learn more visit www.nevasgr.com

Advertisement

About LIFTT

Chaired by the scientist and entrepreneur Stefano Buono, LIFTT’s aim is to encourage technology development and transfer from University to Industry, but also to clear the way from a simple business idea to the creation of an innovative product, offering a dynamic and modern vision of venture capital as applied to Technology Transfer. To date, LIFTThas raised EUR 103,5 million and has completed 47 investments, from a pipeline of +3000 companies, operating in all market sectors, with a particular focus on Deep Tech. www.liftt.com Head of Communications & Investor relations: [email protected]

About Simon Fiduciaria

Simon Fiduciaria is the fiduciary and trust company of Ersel Group which since 1936 has been a specialist in wealth management and a unique company in Italy for its absolute independence, professionalism, quality of service, and direct and personal relationship with the client.

Founded in 1986, Simon Fiduciaria stands out for its independence as well as its operational and professional qualities, to fully meet the needs of its customers. As a reference point for the Italian fiduciary market, with over 7 billion administered assets, Simon Fiduciaria has developed, alongside fiduciary and trust heading services, an innovative service dedicated to large private and institutional assets, with independent and analytical monitoring that offers an aggregated view of allocation, performance, and risks, and highlights potential areas for improvement.

About Sixth Element Capital LLP and the CRT Pioneer Fund

Sixth Element Capital LLP (6EC) is a UK based fund manager, which manages the CRT Pioneer Fund. 6EC’s experienced partners focus on creative and collaborative novel financing solutions designed to fund and manage innovative science in order to bring new therapeutic products and technologies to market, creating long term value and benefit to stakeholders. The CRT Pioneer Fund is a specialist oncology investment fund established by 6EC in 2012. The £70 million fund is dedicated to investments in oncology development programmes in Europe. The fund was established to bridge the investment gap between cancer drug discovery and early clinical development.

For more information, please see www.sixthelementcapital.com

About Claris Ventures

Claris Ventures is a biotech-focused venture capital firm based in Turin (Italy). Its first fund under management, Claris Biotech I, was launched in 2020 to finance high potential biopharma companies arisen from the Italian R&D ecosystem – both local and international. We identify and support innovation in the pharmaceutical space, investing in new companies with transformational drugs under development. We aim at the highest impact possible on highly unmet patients’ needs, building value around strong science. Our pursuit for high potential projects involves every research center, clinical structure and company in the Italian life sciences network, whether the founding team is based in Italy or it includes Italian scientists abroad who have strong links with Italy.

Advertisement

http://www.clarisventures.com/

About 3B Future Health Fund II

3B Future Health Fund II S.C.A. SICAV-RAIF is a Luxembourg based investment fund investing in oncology and rare disease therapeutics in Europe and the United States. The firm’s goal is to identify innovative and promising companies that are developing First-in-Class therapeutics for indications with high unmet patient needs and provide them with the financial resources and strategic guidance they need to succeed. The fund targets companies with strong management teams, a solid scientific foundation, and a clear path to regulatory approval and commercialization. We seek to invest in early-stage companies with promising preclinical data. Additionally, the fund’s investment team has extensive experience in the pharma industry, a track record of success in drug development and identifying high-potential investments. 3B is committed to creating value for its investors while also making a positive impact on the lives of patients. For more information please see www.3bfuturehealth.com

About Astellas Venture Management LLC

Astellas Venture Management LLC (AVM) is the corporate venture capital organization dedicated to reinforcing Astellas Pharma Inc. (Astellas) to accomplish the strategic goals. The venture capital activity of AVM is designated since 2005. Astellas, the ultimate parent company of AVM, headquartered in Tokyo is actively engaged in business as an R&D-driven global pharmaceutical company with the business philosophy to “Contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products”. Through strategic investments in private early-stage companies, the funds aim to mutual-interact with Astellas, leading to partnering/collaboration in the future. AVM will be able to provide portfolio companies with invaluable R&D advice and assistance.

About 2Invest

2Invest AG (2Invest) is an investment company listed on Frankfurt market formed in 2020 from the restructuring of businesses of 4basebio AG.  Our investment objective is primarily but not exclusively to identify and support emerging companies with both strong management teams and ground-breaking technologies in the biotechnology, life sciences and IT sectors. Our ambition is to enable those companies to reach new and meaningful value inflexion points.

View original content:https://www.prnewswire.co.uk/news-releases/neophore-raises-an-additional-9-6m-usd-12-2m-series-b-financing-extension-to-further-progress-drug-discovery-pipeline-302049681.html

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

This Metal Saw Prices increase 200% in 2024 – It Could Happen Again in 2025

Published

on

this-metal-saw-prices-increase-200%-in-2024-–-it-could-happen-again-in-2025

FN Media Group Presents Oilprice.com Market Commentary

LONDON, Nov. 26, 2024 /PRNewswire/ — One of the best performing assets on the planet right now could be a little-known critical strategic critical metal that has exploded 200% this year. It’s the metal that wins wars, and China has banned its export with the intent of stripping the U.S. war machine of its capabilities. Companies mentioned in this release include: Piedmont Lithium (NASDAQ: PLL), Vale S.A. (NYSE: VALE), Uranium Energy Corp (NYSE American: UEC), MP Materials (NYSE: MP), Compass Minerals International (NYSE: CMP).

During WWII, antimony was the hero of the day. It’s a critical element in the production not only of fire-retardant military uniforms and tents, but also in the mass production of many of our means of modern warfare, from bullets and artillery shells to night vision googles, nuclear weapons and anti-tank missiles. Without Antimony, the U.S. could be rendered defenseless in the face of its enemies.

It’s an opportunity that North America-based Military Metals (MILI.CN; MILIF.QB) is pouncing on with a series of strategic acquisitions of past-producing antimony mines and new discoveries from North America to Europe.

That’s why prices skyrocketed this year when China, which controls nearly half the world’s production and three-quarters of its refining, cut the U.S. out of the Antimony supply chain.

The price of antimony doubled in July, 2024, according to S&P Global, hitting a then-record $22,750 per metric ton (antimony ingots 99.65% FOB) by August 6th. By November 15th, the price had hit $25,000 a ton, according to Forbes, for a 212% surge YTD.

The supply squeeze and the 200% price boost has netted investors triple-digit returns this year, first in Australia, where ASX-listed miners have been reaping huge rewards for investors.

Australian media is calling it an “antimony party”, with Larvotto Resources Ltd. (LRV) up over 800%, most of that gained in the past six months after China restricted antimony exports.

Now, everyone’s watching the junior miners to see who is next to benefit from the bounty of Chinese restrictions, and the next one to pop could be Military Metals (MILI.CN; MILIF.QB) who have made a number of acquisitions over the past few months inserting themselves firmly into the picture.

Where the Opportunities Lie

Advertisement

“The surge in prices, which industry participants expect to persist, underscores the West’s vulnerability in relying on top producer China for key minerals and could also force end-users to find alternatives for some applications,” according to Reuters, opening the door wide open for ambitious new entrants to the highly exclusive antimony club.

Miners are rushing the space. In the span of only two days in October alone, we saw Felix Gold Ltd announce plans to take “several steps” toward the goal of establishing a 5,000-metric-ton-per-year antimony mine by the end of 2025.

Australia’s Larvotto, which holds Australia’s biggest antimony deposit, owns the Hillgrove gold-antimony project near Armidale, New South Wales, and that ship has already sailed.

But new entrants like Military Metals could be the next big surge winners, with Forbes now calling this space “the latest to generate short-term profits of more than 100% on money invested”.

The company has two big cards to play right now, following its recent purchase of two Antimony mines and one Tin project.

One card is a triple set of assets in Slovakia in Central Europe, where antimony shortages are making the wider European Union very anxious. By the time China implemented antimony export restrictions in September, having announced the move in August, Europe was already in a critical metals panic. China had already put export restrictions on rare earth minerals gallium and germanium, along with battery metal graphite, in 2023 and 2024, and European refiners have been seeking alternative supplies from Tajikistan, Vietnam and Myanmar while the U.S. is trying to tap India.

Military Metals is hoping to provide a new source of antimony for Europe in Slovakia and for the U.S. in Canada’s Nova Scotia, at a past-producing mine that was the country’s largest during WWI.

 

The Trojarova asset is part of its recent Slovakian acquisition and is one of the European Union’s largest Antimony deposits with a historical resource of over 60,998 tons of Antimony that has a in-situ value of $2 billion at today’s spot prices.

“This acquisition strategically positions Military Metals as a leading explorer and developer of antimony,” CEO Scott Eldridge said in a press release, describing the Slovakian antimony projects as offering “significant potential for rapid advancement, particularly given Slovakia’s strong mining infrastructure and history”.

Advertisement

“We see this as a perfect alignment with the European Union’s Critical Raw Materials Act, opening the door to potential EU funding sources as we advance these projects toward production,” Eldridge added.

In late September 2024, Military Metals moved to acquire the West Gore past-producing antimony/gold mine in Nova Scotia, Canada, conjuring up the ghosts of WWI who also saw demand for antimony soar in a time of global conflict.

Just a month later, on October 24, 2024, Military Metals (MILI.CN; MILIF.QB) moved to consolidate additional territory around West Gore, where historical drilling results from Canada’s biggest antimony mine showing over 7 meters of 10.6 gpt gold and 3.4% antimony.

 

The Pentagon makes Antimony a Top Priority

For U.S. national security, things will have to move quickly, shifting important focus to junior miners willing to bet big on the next market-rattling supply crunch.

It can’t happen fast enough.

Germany has essentially been demilitarized, with its own defense ministry estimating it has about 2 days of ammunition if there is a war with Russia, which it fully expects to happen within the next few years at most.

In March 2024, the European Union allocated 500,000,000 euro under the Act in Support of Ammunition Production (ASAP) to boost output capacity to 2 million shells annually by the end of 2025. But the Western militaries have a major problem.

The U.S. Army, for its part, has set its industrial war room in motion because it was already dealing with an artillery shell supply crunch. It’s planning a major ramp-up in the output of “legacy munitions”, including anti-tank missiles, Stingers and artillery shells. The goal is to increase production of the 155-millimeter artillery shell from 40,000 units/month today to 100,000 units/month by the end of the year. That means a massive ramp-up of antimony supplies that can no longer come from China.

Advertisement

This is a junior miner playing field at its best, making antimony one of the best investment theses of this year and next, and China is feeding the price and supply frenzy with export restrictions. And the news flow for anything antimony is expected to be a media frenzy, with new entrants exponentially picking up the pace of deal-making in this unique space.

Other resource companies to watch:

Piedmont Lithium (NASDAQ: PLL)

Piedmont Lithium is a development-stage company focused on establishing a fully integrated lithium hydroxide business in the United States. Their core operation centers around the Carolina Tin-Spodumene Belt in North Carolina, a region with a history of lithium production. Piedmont aims to be a key supplier of lithium hydroxide, a crucial component in electric vehicle batteries and energy storage systems, to the burgeoning U.S. market.

This company matters because they are addressing a critical need for domestically sourced lithium. The U.S. currently relies heavily on imports for its lithium supply, creating potential vulnerabilities in the supply chain. Piedmont’s operations contribute to a more secure and resilient domestic supply of this essential mineral, which is vital for the production of advanced batteries used in defense applications such as electric vehicles, drones, and communication systems.

Vale S.A. (NYSE: VALE)

Vale S.A. is a Brazilian multinational corporation and one of the world’s largest producers of iron ore and nickel. Iron ore is a key ingredient in steelmaking, while nickel is a crucial component in stainless steel and various alloys used in aerospace, defense, and other high-performance applications. Vale operates globally, with significant mining and production facilities in Brazil.

Vale’s commitment to sustainable mining practices and social responsibility is also noteworthy. The company has implemented various initiatives to reduce its environmental impact, promote biodiversity, and support local communities.

Uranium Energy Corp (NYSE American: UEC)

Uranium Energy Corp is a U.S.-based uranium mining and exploration company with a focus on in-situ recovery (ISR) mining projects in Texas, Wyoming, and New Mexico. ISR mining is a less invasive and more environmentally friendly method of uranium extraction compared to traditional open-pit mining. Uranium Energy Corp has a portfolio of permitted and development-stage ISR projects, positioning them to be a significant contributor to the U.S. uranium supply.

Advertisement

This company is important because they are contributing to the revitalization of the U.S. uranium mining industry. After a period of decline, the U.S. is increasingly recognizing the importance of securing a domestic supply of uranium for both energy security and national security purposes.

MP Materials (NYSE: MP)

MP Materials owns and operates Mountain Pass, the only integrated rare earth mining and processing site in North America. Rare earth elements are essential for a wide range of technologies, including defense applications such as guidance systems, lasers, and radar. MP Materials’ role in securing a domestic supply of these critical minerals is vital for reducing dependence on foreign sources, particularly China, which currently dominates the rare earth market.

The concentration of rare earth production in China poses a potential risk to national security, as it creates a vulnerability to supply chain disruptions or geopolitical tensions. MP Materials’ operations at Mountain Pass contribute to diversifying the rare earth supply chain and ensuring that the U.S. has access to these critical materials for its defense needs. This reduces reliance on potentially adversarial nations and strengthens the resilience of the U.S. defense industrial base.

Compass Minerals International (NYSE: CMP)

based in Overland Park, Kansas, is a leading provider of essential minerals, including salt, sulfate of potash, magnesium chloride, and even sustainable lithium. The company’s diversified product mix serves a wide range of markets, including agriculture, consumer deicing, water conditioning, and various industrial applications.

Beyond its current offerings, Compass Minerals is investing in new technologies and methods to enhance the efficiency and environmental sustainability of its operations. The company’s focus on innovation is particularly evident in its approach to lithium extraction, where it aims to capitalize on the growing demand in the electric vehicle market. This strategic direction not only diversifies their portfolio but also positions Compass Minerals as a key player in the transition to a more sustainable global economy.

**IMPORTANT! BY READING OUR CONTENT YOU EXPLICITLY AGREE TO THE FOLLOWING. PLEASE READ CAREFULLY**

Forward-Looking Statements

This publication contains forward-looking information which is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ from those projected in the forward-looking statements. The forward-looking statements in this publication are based on current expectations and assumptions about future events, geopolitical developments, trade policies, market conditions, the company’s strategic initiatives to address the critical shortage of antimony, and current expectations, estimates, and projections about the industry and markets in which the company operates. Factors that could change or prevent these statements from coming to fruition include, but are not limited to, the potential impact of Trump’s victory in the U.S. elections on various industries and specific companies, changes in government policies, market conditions, regulatory developments, geopolitical events and the company’s ability to successfully acquire and develop new antimony resources and fluctuations in antimony prices. The forward-looking information contained herein is given as of the date hereof and we assume no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.

Advertisement

DISCLAIMERS

This communication is for entertainment purposes only. Never invest purely based on our communication. We have not been compensated by the companies mentioned in this article. While the opinions expressed in this article are based on information believed to be accurate and reliable, such information in our communications and on our website has not been independently verified and is not guaranteed to be correct. The content of this article is based solely on our opinions which are based on very limited analysis, and we are not professional analysts or advisors.

SHARE OWNERSHIP. The owner of Oilprice.com owns shares of the companies featured in this article and therefore has an incentive to see the featured companies’ stock perform well. The owner of Oilprice.com will not notify the market when it decides to buy more or sell shares of the featured companies in the market. The owner of Oilprice.com will be buying and selling shares of the featured companies for its own profit and may take this opportunity to liquidate a portion of its position. Accordingly, our views and opinions in this article are subject to bias, and why we stress that you should conduct your own extensive due diligence regarding the featured companies as well as seek the advice of your professional financial advisor or a registered broker-dealer before you consider investing in any securities of the featured companies or otherwise.

NOT AN INVESTMENT ADVISOR. Oilprice.com is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. You should not treat any opinion expressed herein as an inducement to make a particular investment or to follow a particular strategy, but only as an expression of opinion. The opinions expressed herein do not consider the suitability of any investment with your particular objectives or risk tolerance. Investments or strategies mentioned in this article and on our website may not be suitable for you and are not intended as recommendations.

ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making any investment. This communication should not be used as a basis for making any investment in any securities. Past performance is not indicative of future results.

RISK OF INVESTING. Investing is inherently risky. Do not trade with money you cannot afford to lose. There is a real risk of loss (including total loss of investment) in following any strategy or investment discussed in this article or on our website. This is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities or the solicitation of any vote in any jurisdiction. No representation is being made as to the future price of securities mentioned herein, or that any stock acquisition will or is likely to achieve profits.

DISCLAIMER: OilPrice.com is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with OilPrice.com or any company mentioned herein. The commentary, views and opinions expressed in this release by OilPrice.com are solely those of OilPrice.com and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.

FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:
Media Contact e-mail: [email protected] U.S. Phone: +1(954)345-0611

Advertisement

View original content:https://www.prnewswire.co.uk/news-releases/this-metal-saw-prices-increase-200-in-2024—it-could-happen-again-in-2025-302315841.html

Continue Reading

Fintech PR

China Immigration Service Hotline 12367 to Offer Russian, Japanese and Korean Services

Published

on

china-immigration-service-hotline-12367-to-offer-russian,-japanese-and-korean-services

BEIJING, Nov. 26, 2024 /PRNewswire/ — From November 26, 2024, the telephone terminal of the China Immigration Service Hotline 12367 will support Russian, Japanese and Korean language services, in addition to the existing bilingual Chinese and English services. Users who dial 12367 can select the language service as needed by following the instructions of the voice prompt. For any user selecting Russian, Japanese or Korean language service, the hotline will establish a communication channel encompassing the user, an interpreter and a hotline operator to provide one-stop immediate services. This new move aims to deliver more convenient immigration services for foreigners in China and those planning to visit China, and to facilitate the development of a market-oriented, law-based and internationalized first-class business environment in the country.

As an integrated “customer service center” established by the National Immigration Administration (NIA) of China for both Chinese and foreign exit-entry personnel, the China Immigration Service Hotline 12367, including a telephone terminal, the “National Immigration Administration Government Service Platform 12367″(移民局12367) App, WeChat and Alipay mini-programs, a website, etc., provides one-stop consultation services through intelligent, real-time and 24/7 responses. It serves as an important platform for Chinese and foreign citizens and enterprises to address their urgent needs and problems in terms of China’s immigration management. Since the start of its operation on April 8, 2021, the hotline has received over 14 million phone calls regarding policy consultation, opinions and suggestions, and other issues concerning China’s immigration management from Chinese and foreign citizens. So far, its services have reached 156 countries and regions around the world, with its ratio of first-call resolution reaching 99.9% and its average satisfaction rate reaching 98.6%. The hotline is playing a crucial role in maintaining the order of immigration management, driving economic and social development, and promoting exchanges between Chinese and foreign citizens.

Moving forward, NIA will continue optimizing the operation of the hotline by constantly expanding its service channels and adding new functions, to actively cater to the needs of convenient services for Chinese and foreign citizens entering and exiting the country. NIA strives to make new contributions in facilitating the personnel exchanges between China and the rest of the world, high-level opening-up and high-quality development.

View original content:https://www.prnewswire.co.uk/news-releases/china-immigration-service-hotline-12367-to-offer-russian-japanese-and-korean-services-302316517.html

Continue Reading

Fintech PR

Exyte Receives Micron’s Outstanding Supplier Performance Award in Supplier Diversity

Published

on

exyte-receives-micron’s-outstanding-supplier-performance-award-in-supplier-diversity

STUTTGART, Germany, Nov. 26, 2024 /PRNewswire/ — Exyte, a global leader in the design, engineering, and delivery of high-tech facilities, was presented with the Outstanding Supplier Performance Award in Supplier Diversity at the Micron Supplier Day 2024. The event, held in San Francisco, CA, USA, was attended by top-level management of Micron and its suppliers, including Exyte. This award highlights Exyte’s commitment to excellence in quality, innovation, and collaboration with Micron, a global leader in memory and storage solutions.

 

 

“I am truly grateful and honored to be receiving this award on behalf of Exyte. It is always great to receive such recognition directly from our clients, more so from an industry leader like Micron. I am very proud of our employees involved, that their exceptional hard work and commitment to deliver for Micron are highly appreciated,” commented Dr. Wolfgang Büchele, Exyte Group Chairman and CEO, in his award acceptance speech.

The Micron Global Supplier Award is an annual accolade that celebrates outstanding supplier performance across twelve categories. The awards are determined through a comprehensive evaluation process that scores suppliers on various criteria.

Exyte’s long-standing collaboration with Micron stretches back for more than a decade. Exyte has fostered a strong cooperation with Micron through major projects in both Asia and the USA.

For over 45 years, Micron’s innovative memory solutions have been instrumental to the world’s most significant technological advancements. Exyte is privileged to play a role in helping elevate the capabilities of customers such as Micron as Exyte continues with its mission of creating a better future for all, together.

“My heartfelt congratulations to all our team members for winning this award. I am extremely thrilled for them as this win is a remarkable testament to the collective effort and dedication they bring to their work at Micron,” lauded Mark Garvey, Exyte Executive Board Member and CEO of Global Business Unit Advanced Technology Facilities. “I would also like to thank Micron for their continuous support and in recognizing the contributions of their suppliers. I look forward to reinforcing Exyte’s collaboration with Micron in 2025 and beyond,” Garvey added.

About Exyte

Exyte is a global leader in the design, engineering, and delivery of ultra-clean and sustainable facilities for high-tech industries. With cutting-edge expertise developed over more than a century, the company serves clients in the sophisticated markets of semiconductors, battery cells, pharmaceuticals, biotechnology, and data centers. Exyte offers a full range of services from consulting to managing the implementation of turnkey solutions with the highest standards in safety and quality to its customers worldwide. Exyte creates a better future by enabling key industries to enhance the quality of modern life. In 2023, the company generated sales of €7.1 billion with around 9,700 employees worldwide.

Advertisement

Contact

Samy Abdel Aal
Public Relations Manager
Mobile: +49 172 840 33 01
Phone: +49 711 880 44 696
[email protected]

www.exyte.net

Photo: https://mma.prnewswire.com/media/2567626/Exyte.jpg
Photo: https://mma.prnewswire.com/media/2567627/Exyte_1.jpg
Logo:  https://mma.prnewswire.com/media/1487100/5048559/Exyte_Logo.jpg

 

Exyte CEO Wolfgang Büchele receives the award from Fran Dillard, Micron's Chief Diversity Inclusion Officer.

 

Exyte Logo

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/exyte-receives-microns-outstanding-supplier-performance-award-in-supplier-diversity-302316477.html

Continue Reading

Trending